Lipidomic profiling of human serum enables detection of
pancreatic cancer

J 2022

Lipidomic profiling of human serum enables detection of pancreatic cancer

WOLRAB, Denise, Robert JIRASKO, Eva CIFKOVA, Marcus HORING, Ding MEI et. al.

Základní údaje

Originální název

Lipidomic profiling of human serum enables detection of pancreatic cancer

Autoři

WOLRAB, Denise, Robert JIRASKO (203 Česká republika), Eva CIFKOVA (203 Česká republika), Marcus HORING, Ding MEI, Michaela CHOCHOLOUSKOVA (203 Česká republika), Ondrej PETERKA (203 Česká republika), Jakub IDKOWIAK (203 Česká republika), Tereza HRNCIAROVA (203 Česká republika), Ladislav KUCHAR (203 Česká republika), Robert AHRENDS, Radana BRUMAROVA (203 Česká republika), David FRIEDECKY (203 Česká republika), Gabriel VIVO-TRUYOLS, Pavel SKRHA (203 Česká republika), Jan SKRHA (203 Česká republika), Radek KUCERA (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Gerhard LIEBISCH, Ralph BURKHARDT, Markus R. WENK, Amaury CAZENAVE-GASSIOT, Petr KARASEK (203 Česká republika), Ivo NOVOTNY (203 Česká republika), Kristína GREPLOVÁ (203 Česká republika, domácí), Roman HRSTKA (203 Česká republika) a Michal HOLCAPEK (203 Česká republika, garant)

Vydání

Nature Communications, BERLIN, Nature Publishing Group, 2022, 2041-1723

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 16.600

Kód RIV

RIV/00216224:14110/22:00127203

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41467-021-27765-9

UT WoS

000797924100001

Klíčová slova anglicky

lipidomic profiling; human serum; pancreatic cancer

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 2. 2024 11:26, Mgr. Tereza Miškechová

Anotace

V originále

Pancreatic cancer has the worst prognosis among all cancers. Cancer screening of body fluids may improve the survival time prognosis of patients, who are often diagnosed too late at an incurable stage. Several studies report the dysregulation of lipid metabolism in tumor cells, suggesting that changes in the blood lipidome may accompany tumor growth. Here we show that the comprehensive mass spectrometric determination of a wide range of serum lipids reveals statistically significant differences between pancreatic cancer patients and healthy controls, as visualized by multivariate data analysis. Three phases of biomarker discovery research (discovery, qualification, and verification) are applied for 830 samples in total, which shows the dysregulation of some very long chain sphingomyelins, ceramides, and (lyso) phosphatidylcholines. The sensitivity and specificity to diagnose pancreatic cancer are over 90%, which outperforms CA 19-9, especially at an early stage, and is comparable to established diagnostic imaging methods. Furthermore, selected lipid species indicate a potential as prognostic biomarkers.

Návaznosti

90125, velká výzkumná infrastruktura

Název: BBMRI-CZ III

Citovat

WOLRAB, Denise, Robert JIRASKO, Eva CIFKOVA, Marcus HORING, Ding MEI, Michaela CHOCHOLOUSKOVA, Ondrej PETERKA, Jakub IDKOWIAK, Tereza HRNCIAROVA, Ladislav KUCHAR, Robert AHRENDS, Radana BRUMAROVA, David FRIEDECKY, Gabriel VIVO-TRUYOLS, Pavel SKRHA, Jan SKRHA, Radek KUCERA, Bohuslav MELICHAR, Gerhard LIEBISCH, Ralph BURKHARDT, Markus R. WENK, Amaury CAZENAVE-GASSIOT, Petr KARASEK, Ivo NOVOTNY, Kristína GREPLOVÁ, Roman HRSTKA a Michal HOLCAPEK. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nature Communications. BERLIN: Nature Publishing Group, 2022, roč. 13, č. 1, s. 1-16. ISSN 2041-1723. Dostupné z: https://dx.doi.org/10.1038/s41467-021-27765-9.

@article{2233286,
   author = {Wolrab, Denise and Jirasko, Robert and Cifkova, Eva and Horing, Marcus and Mei, Ding and Chocholouskova, Michaela and Peterka, Ondrej and Idkowiak, Jakub and Hrnciarova, Tereza and Kuchar, Ladislav and Ahrends, Robert and Brumarova, Radana and Friedecky, David and VivoandTruyols, Gabriel and Skrha, Pavel and Skrha, Jan and Kucera, Radek and Melichar, Bohuslav and Liebisch, Gerhard and Burkhardt, Ralph and Wenk, Markus R. and CazenaveandGassiot, Amaury and Karasek, Petr and Novotny, Ivo and Greplová, Kristína and Hrstka, Roman and Holcapek, Michal},
   article_location = {BERLIN},
   article_number = {1},
   doi = {http://dx.doi.org/10.1038/s41467-021-27765-9},
   keywords = {lipidomic profiling; human serum; pancreatic cancer},
   language = {eng},
   issn = {2041-1723},
   journal = {Nature Communications},
   title = {Lipidomic profiling of human serum enables detection of pancreatic cancer},
   url = {https://www.nature.com/articles/s41467-021-27765-9},
   volume = {13},
   year = {2022}
}

TY  - JOUR
ID  - 2233286
AU  - Wolrab, Denise - Jirasko, Robert - Cifkova, Eva - Horing, Marcus - Mei, Ding - Chocholouskova, Michaela - Peterka, Ondrej - Idkowiak, Jakub - Hrnciarova, Tereza - Kuchar, Ladislav - Ahrends, Robert - Brumarova, Radana - Friedecky, David - Vivo-Truyols, Gabriel - Skrha, Pavel - Skrha, Jan - Kucera, Radek - Melichar, Bohuslav - Liebisch, Gerhard - Burkhardt, Ralph - Wenk, Markus R. - Cazenave-Gassiot, Amaury - Karasek, Petr - Novotny, Ivo - Greplová, Kristína - Hrstka, Roman - Holcapek, Michal
PY  - 2022
TI  - Lipidomic profiling of human serum enables detection of pancreatic cancer
JF  - Nature Communications
VL  - 13
IS  - 1
SP  - 1-16
EP  - 1-16
PB  - Nature Publishing Group
SN  - 20411723
KW  - lipidomic profiling
KW  - human serum
KW  - pancreatic cancer
UR  - https://www.nature.com/articles/s41467-021-27765-9
N2  - Pancreatic cancer has the worst prognosis among all cancers. Cancer screening of body fluids may improve the survival time prognosis of patients, who are often diagnosed too late at an incurable stage. Several studies report the dysregulation of lipid metabolism in tumor cells, suggesting that changes in the blood lipidome may accompany tumor growth. Here we show that the comprehensive mass spectrometric determination of a wide range of serum lipids reveals statistically significant differences between pancreatic cancer patients and healthy controls, as visualized by multivariate data analysis. Three phases of biomarker discovery research (discovery, qualification, and verification) are applied for 830 samples in total, which shows the dysregulation of some very long chain sphingomyelins, ceramides, and (lyso) phosphatidylcholines. The sensitivity and specificity to diagnose pancreatic cancer are over 90%, which outperforms CA 19-9, especially at an early stage, and is comparable to established diagnostic imaging methods. Furthermore, selected lipid species indicate a potential as prognostic biomarkers.
ER  -

WOLRAB, Denise, Robert JIRASKO, Eva CIFKOVA, Marcus HORING, Ding MEI, Michaela CHOCHOLOUSKOVA, Ondrej PETERKA, Jakub IDKOWIAK, Tereza HRNCIAROVA, Ladislav KUCHAR, Robert AHRENDS, Radana BRUMAROVA, David FRIEDECKY, Gabriel VIVO-TRUYOLS, Pavel SKRHA, Jan SKRHA, Radek KUCERA, Bohuslav MELICHAR, Gerhard LIEBISCH, Ralph BURKHARDT, Markus R. WENK, Amaury CAZENAVE-GASSIOT, Petr KARASEK, Ivo NOVOTNY, Kristína GREPLOVÁ, Roman HRSTKA a Michal HOLCAPEK. Lipidomic profiling of human serum enables detection of pancreatic cancer. \textit{Nature Communications}. BERLIN: Nature Publishing Group, 2022, roč.~13, č.~1, s.~1-16. ISSN~2041-1723. Dostupné z: https://dx.doi.org/10.1038/s41467-021-27765-9.

Podrobný výpis o publikaci